Eli Lilly and Company (LLY)
-NYSE 52.35 
0.01(0.02%) Jun 18, 4:02PM EDT|After Hours
:
52.35 0.00 (0.00%) Jun 18, 5:54PM EDT
| Prev Close: | 52.36 |
|---|
| Open: | 52.46 |
|---|
| Bid: | 52.35 x 500 |
|---|
| Ask: | 56.00 x 100 |
|---|
| 1y Target Est: | 56.47 |
|---|
| Beta: | 0.35 |
|---|
| Next Earnings Date: | 24-Jul-13 |
|---|
| Day's Range: | 51.69 - 52.72 |
|---|
| 52wk Range: | 41.41 - 58.40 |
|---|
| Volume: | 5,164,737 |
|---|
| Avg Vol (3m): | 4,981,910 |
|---|
| Market Cap: | 56.75B |
|---|
| P/E (ttm): | 12.58 |
|---|
| EPS (ttm): | 4.16 |
|---|
| Div & Yield: | 1.96 (3.80%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- [$$] Lilly's Zyprexa Under Scrutinyat The Wall Street Journal(Tue, Jun 18)
- The FDA Might Pull This Drug From the Market (and Why It Doesn't Matter)at Motley Fool(Tue, Jun 18)
- FDA investigates Zyprexa Relprevv patient deathsAP(Tue, Jun 18)
- Daily Dividend Report: SRE, LLY, AMAT, RL, PETMat Forbes(Tue, Jun 18)
- CryoPort's Game-Changer In Frozen Biological Shippingat Seeking Alpha(Tue, Jun 18)
- 'Unexplained' deaths from antipsychotic drug probed by FDAat MarketWatch(Tue, Jun 18)
- FDA Investigates Two 'Unexplained' Deaths Possibly Related to Lilly Injectionat Fox Business(Tue, Jun 18)
- FDA Investigating Lilly’s Zyprexa Injection After Two Dieat Bloomberg(Tue, Jun 18)
- FDA probes deaths of two patients on Lilly schizophrenia drugat Reuters(Tue, Jun 18)
- Lilly Declares Third-Quarter 2013 DividendPR Newswire(Tue, Jun 18)
- J&J studying deaths of two patients on long-acting Zyprexaat Reuters(Tue, Jun 18)
- FDA investigating two deaths of patients taking Lilly's Zyprexatheflyonthewall.com(Tue, Jun 18)
- Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Marketat Seeking Alpha(Tue, Jun 18)
- 4 Healthcare Stock Stories Making Waves On Mondayat Wall St. Cheat Sheet(Mon, Jun 17)
- Successor To Humira? AbbVie And Galapagos Work On Itat Seeking Alpha(Mon, Jun 17)
Key Statistics
| Forward P/E (1 yr): | 19.11 |
|---|
| P/S (ttm): | 2.51 |
|---|
| Ex-Dividend Date: | 14-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.93 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.00 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | -5.68 |
|---|
Business Summary
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. The companys neuroscience products treat major depressive disorders; schizophrenia, acute mixed or manic episodes associated with bipolar I...
View More